Summary:
The purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the brain (non-central nervous system (CNS) systemic embolism) in participants with atrial fibrillation.
Qualified Participants Must:
• Be at least 18 years old
• Have atrial fibrillation or flutter
• Have a qualifying risk factor
Qualified Participants May Receive:
Study drug or placebo and a stipend up to $85 after each completed office visit